AOS to face competition
Wednesday, 25 June, 2008
Advanced Ocular Systems (ASX: AOS) will have to contend with a new competitor for its Triesence injectable triamcinolone acetonide anti-inflammatory, company directors warned the market yesterday.
The new product, known as Trivaris, is manufactured by Allergan. The FDA recently approved the drug for sale.
It will be in direct competition with Triesence, which was developed by AOS and is sold under license through Alcon.
The potential effect on the company's royalties revenues is currently unclear, AOS said.
Injectable triamcinolone acetonide is mainly used to treat inflammation of the eyes and other similar ocular diseases and disorders.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
